Can GLP-1 Therapy Help PsA Beyond Losing Weight?
Audrey Gibson, PA-C | Abstract 0373 | ACR 2026
Transcription
Hi, I'm Audrey Gibson, a rheumatology physician assistant reporting for RheumNow from ACR Convergence 2026 in Orlando. And I want to discuss abstract number 0373 presented by Dr. Meta and colleagues because it strives to answer a question that is becoming increasingly important in our clinics. Can GLP-1 therapy help psoriatic arthritis beyond the effect of just losing weight?
The title of this abstract is "Treatment with glucagon-like peptide-1 receptor agonist is associated with lower disease activity in pain and psoriatic arthritis independent of weight change." We know that obesity is common in psoriatic arthritis and we know that it complicates management. Patients may have more pain, disability, cardiometabolic disease, and sometimes a lower likelihood of achieving treatment targets.
The Toronto investigators used a longitudinal cohort from 2017 through December 2025. Patients with at least one year of GLP-1 use, available clinic visits, and eligible matched controls were included. Controls were matched on body mass index, CPDAI, and calendar year using the closest pre-initiation visit. Linear mixed models assessed the association between GLP-1 use and the disease activity outcomes.
CPDAI, DAPSA, PsAID, and HAQ at follow-up at 6 months and 12 months, adjusting for baseline disease activity and timing of assessments, to estimate total effects of GLP-1 and its duration of use on disease activity. A sensitivity analysis was then carried out after adjusting for change in BMI to estimate the direct effect of GLP-1 on disease activity. Analyses were repeated after stratifying for the concurrent PsA treatment.
They compared those patients with eligible controls and examined both patient-reported and objective outcomes. The investigators found that at 12 months more than a 5% weight loss was achieved in 44.4% of patients taking incretin therapy versus 12.8% of controls. They also found modest improvements in CPDAI, DAPSA, and patient-reported pain associated with medication exposure. After additional adjustment for BMI change, these associations persisted, suggesting effects were independent of weight loss.
No significant associations were observed for CRP, swollen joint count, tender joint count, or PsAID. When stratified by concurrent PsA treatment, effects were more prominent in the non-biologic DMARD group compared to the biologic DMARD group.
The bigger story is exciting. Rheumatology and metabolic medicine are moving closer together. This study gives us a reason to pursue prospective trials with imaging and inflammatory endpoints. I'm Audrey Gibson at ACR Convergence 2026. Follow RheumNow for continued coverage of ACR, and thanks.
The title of this abstract is "Treatment with glucagon-like peptide-1 receptor agonist is associated with lower disease activity in pain and psoriatic arthritis independent of weight change." We know that obesity is common in psoriatic arthritis and we know that it complicates management. Patients may have more pain, disability, cardiometabolic disease, and sometimes a lower likelihood of achieving treatment targets.
The Toronto investigators used a longitudinal cohort from 2017 through December 2025. Patients with at least one year of GLP-1 use, available clinic visits, and eligible matched controls were included. Controls were matched on body mass index, CPDAI, and calendar year using the closest pre-initiation visit. Linear mixed models assessed the association between GLP-1 use and the disease activity outcomes.
CPDAI, DAPSA, PsAID, and HAQ at follow-up at 6 months and 12 months, adjusting for baseline disease activity and timing of assessments, to estimate total effects of GLP-1 and its duration of use on disease activity. A sensitivity analysis was then carried out after adjusting for change in BMI to estimate the direct effect of GLP-1 on disease activity. Analyses were repeated after stratifying for the concurrent PsA treatment.
They compared those patients with eligible controls and examined both patient-reported and objective outcomes. The investigators found that at 12 months more than a 5% weight loss was achieved in 44.4% of patients taking incretin therapy versus 12.8% of controls. They also found modest improvements in CPDAI, DAPSA, and patient-reported pain associated with medication exposure. After additional adjustment for BMI change, these associations persisted, suggesting effects were independent of weight loss.
No significant associations were observed for CRP, swollen joint count, tender joint count, or PsAID. When stratified by concurrent PsA treatment, effects were more prominent in the non-biologic DMARD group compared to the biologic DMARD group.
The bigger story is exciting. Rheumatology and metabolic medicine are moving closer together. This study gives us a reason to pursue prospective trials with imaging and inflammatory endpoints. I'm Audrey Gibson at ACR Convergence 2026. Follow RheumNow for continued coverage of ACR, and thanks.
Recommended videos
-
Rheumatoid Arthritis
GLP-1 Drugs in Osteoarthritis and Rheumatoid Arthritis
-
-
General Rheumatology
TRIUMPH-4 Retatrutide GLP-1 in Osteoarthritis

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.